

Supplementary Figure 18. Targeting CD36 significantly enhances the efficacy of PD-1 therapy. Hepa1-6 cells were subcutaneously implanted into the flanks of C57BL/6 mice. The mice were then treated with anti-IgG or anti-PD-1. Tumor images (A) and tumor weights (B) at the endpoint of the experiment. n=6 for each group. Serum MDA levels (C) and serum iron levels (D). n=3 samples per condition. Intracellular lipid ROS (E) and Fe^{2+} (F) levels in tumor-infiltrating $CD8^+$ T cells. n=3 samples per condition. Percentages of PD-1^+ (G), TIM-3^+ (H), TIGIT$^+$ (I), CTLA4^+ (J) and TNFα^+ (K) cells in tumor-infiltrating $CD8^+$ T cells. n=3 samples per condition.